FMP

FMP

Enter

ETNB - 89bio, Inc.

photo-url-https://images.financialmodelingprep.com/symbol/ETNB.png

89bio, Inc.

ETNB

NASDAQ

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

6.75 USD

0.17 (2.52%)

Historical Prices

From:

To:

6.536.556.66.656.76.756.7909:30 AM09:57 AM10:14 AM10:34 AM10:50 AM11:06 AM11:24 AM11:43 AM12:06 PM12:30 PM12:46 PM01:07 PM01:24 PM01:45 PM02:02 PM02:28 PM02:47 PM03:08 PM03:25 PM03:41 PM03:58 PM

About

ceo

Mr. Rohan Palekar

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

CIK

0001785173

ISIN

US2825591033

CUSIP

282559103

Address

142 Sansome Street

Phone

415 432 9270

Country

US

Employee

70

IPO Date

Nov 11, 2019

Financial Statement

-150M-120M-90M-60M-30M030M2023 Q32023 Q42024 Q12024 Q22024 Q3RevenueNet Income

Earnings

-1.5-1.2-0.9-0.6-0.302023 Q12023 Q22023 Q32023 Q42024 Q12024 Q22024 Q32024 Q4EPS Consensus

ETNB Financial Summary

CIK

0001785173

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

282559103

ISIN

US2825591033

Country

US

Price

6.75

Beta

0.98

Volume Avg.

1.05M

Market Cap

793.68M

Shares

-

52-Week

5.986-16.63

DCF

4.06

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-2.28

P/B

-

Website

https://www.89bio.com

Upgrades and Downgrades

We are unable to load the data!

fmp-logo

Latest ETNB News

Seeking Alpha

May 23, 2024

89bio: Pegozafermin Could Be A Game-Changer For Liver Diseas...

89bio is a clinical-stage biopharmaceutical company that develops therapies for liver and cardiometabolic conditions. Their drug candidate, pegozafermin, has shown positive results in reducing liver fat and insulin resistance and is in phase 3 trials for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin has the potential to tap into a large market and has been granted FDA Breakthrough Therapy designation for treating MASH with fibrosis.

GlobeNewsWire

May 22, 2024

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafe...

-Poster presentation selected for the EASL Poster Tour, a dedicated discussion session- -Poster presentation selected for the EASL Poster Tour, a dedicated discussion session-

Zacks Investment Research

May 6, 2024

All You Need to Know About 89BIO (ETNB) Rating Upgrade to Bu...

89BIO (ETNB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

24/7 Wall Street

Mar 10, 2024

Buffett Loads Up on This Stock Again, Plus CEO Insider Buyin...

In the wake of a media giant's quarterly report, the Oracle of Omaha is again bolstering his stake in the tracking stocks with some huge insider purchases.

Zacks Investment Research

Mar 5, 2024

Wall Street Analysts Believe 89BIO (ETNB) Could Rally 121.5%...

The average of price targets set by Wall Street analysts indicates a potential upside of 121.5% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research

Mar 5, 2024

89BIO (ETNB) Just Overtook the 200-Day Moving Average

After reaching an important support level, 89BIO (ETNB) could be a good stock pick from a technical perspective. ETNB surpassed resistance at the 200-day moving average, suggesting a long-term bullish trend.

Seeking Alpha

Dec 6, 2023

89bio: Despite Peer Trial Setback, Potential Remains In NASH

89bio, Inc.'s successful end-of-phase 2 meeting with the FDA gained alignment for Potential Accelerated Approval of pegozafermin; such studies to be advanced are ENLIGHTEN-Cirrhosis and ENLIGHTEN-Fibrosis. Akero will report 96-week data from the SYMMETRY study of efruxifermin for F4 NASH patients in Q1 of 2024; Success for Akero could mean a boost in value for 89bio. The non-alcoholic steatohepatitis market size is projected to reach $24.26 billion by 2028.

Seeking Alpha

Oct 26, 2023

89bio's Low Price Presents An Opportunity

89bio, Inc. stock dropped along with other NASH players after Akero's efruxifermin failed a phase 2 trial. Despite the drop, 89bio remains attractive with excellent phase 2 data and strong financials. 89bio's pegozafermin has shown positive results in reducing fibrosis and liver fat, and there is still potential for FGF21 molecules in the NASH field.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep